Abstract
More than 90 percent of bladder cancers are transitional cell carcinoma (TCC). Superficial TCC is defined as a transitional cell tumor that is confined to the mucosa (Stages T(a) or carcinoma in situ) or that has invaded the lamina propria (Stage T1). When treating patients with superficial bladder cancer, urologists are faced with a number of important tasks. First, the initial tumor or tumors must be removed. Second, the other parts of the urothelium must be assessed for the presence of premalignant or malignant abnormalities. Third, the depth and extent of invasion (i.e., tumor stage) must be determined. Fourth, the clinician must decide whether additional treatment (e.g., intravesical chemotherapy or immunotherapy, cystectomy, or radiotherapy) is indicated. Finally, the patient must be monitored for the development of subsequent tumors. This article provides an overview of the management of superficial bladder cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 5-10 |
| Number of pages | 6 |
| Journal | Urology |
| Volume | 40 |
| Issue number | 6 SUPPL. |
| State | Published - Dec 1 1992 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Managing superficial bladder cancer : An overview. / Soloway, M. S.
In: Urology, Vol. 40, No. 6 SUPPL., 01.12.1992, p. 5-10.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Managing superficial bladder cancer
T2 - An overview
AU - Soloway, M. S.
PY - 1992/12/1
Y1 - 1992/12/1
N2 - More than 90 percent of bladder cancers are transitional cell carcinoma (TCC). Superficial TCC is defined as a transitional cell tumor that is confined to the mucosa (Stages T(a) or carcinoma in situ) or that has invaded the lamina propria (Stage T1). When treating patients with superficial bladder cancer, urologists are faced with a number of important tasks. First, the initial tumor or tumors must be removed. Second, the other parts of the urothelium must be assessed for the presence of premalignant or malignant abnormalities. Third, the depth and extent of invasion (i.e., tumor stage) must be determined. Fourth, the clinician must decide whether additional treatment (e.g., intravesical chemotherapy or immunotherapy, cystectomy, or radiotherapy) is indicated. Finally, the patient must be monitored for the development of subsequent tumors. This article provides an overview of the management of superficial bladder cancer.
AB - More than 90 percent of bladder cancers are transitional cell carcinoma (TCC). Superficial TCC is defined as a transitional cell tumor that is confined to the mucosa (Stages T(a) or carcinoma in situ) or that has invaded the lamina propria (Stage T1). When treating patients with superficial bladder cancer, urologists are faced with a number of important tasks. First, the initial tumor or tumors must be removed. Second, the other parts of the urothelium must be assessed for the presence of premalignant or malignant abnormalities. Third, the depth and extent of invasion (i.e., tumor stage) must be determined. Fourth, the clinician must decide whether additional treatment (e.g., intravesical chemotherapy or immunotherapy, cystectomy, or radiotherapy) is indicated. Finally, the patient must be monitored for the development of subsequent tumors. This article provides an overview of the management of superficial bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=0027054534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027054534&partnerID=8YFLogxK
M3 - Article
VL - 40
SP - 5
EP - 10
JO - Urology
JF - Urology
SN - 0090-4295
IS - 6 SUPPL.
ER -